

GETINGE GROUP



GETINGE GROUP

Interim Report

January – December 2009

January 26, 2009

Johan Malmquist, CEO

Ulf Grunander, CFO

Q4 2009 Highlights

- Demand in the US continues to improve
- Demand in Western Europe remains stable
- Integration of BS Cardiac & Vascular surgery divisions completed
- Datascope integration nears completion
- Continuous expansion of market organisations in emerging economies
- Additional restructuring charges of 109 Msek for improved competitiveness in Infection Control and Extended Care
- Strong cash generation

Q4 2009 Development of organic order intake

	2009				2009			
	Q4				YTD			
	MS	EC	IC	TOT	MS	EC	IC	TOT
Europe	10.7%	-1.4%	9.0%	6.3%	2.5%	-4.6%	3.8%	0.2%
USA and Canada	11.5%	7.0%	14.0%	10.8%	1.4%	-4.9%	1.7%	-0.6%
Asia and Australia	10.5%	-3.9%	-6.2%	4.0%	11.8%	-0.1%	1.1%	6.7%
Rest of the world	5.9%	-23.6%	-21.8%	-2.8%	2.5%	-13.5%	-54.0%	-10.2%
Total	10.6%	0.6%	7.6%	6.9%	3.7%	-4.5%	0.7%	0.4%

Q4 2009 Group results

- Cost synergies and mix strengthens gross margins
- Additional restructuring charges of 109 MSEK

	2009	2008	Change	2009	2008	Change
<i>SEK million</i>	Q4	Q4	%	YTD	YTD	%
Net sales, SEK million	6 845	6 423	6.6%	22 816	19 272	18.4%
Gross margin	49.4%	47.7%	1.7%	49.3%	48.4%	0.9%
Operating cost, SEK million	-1 971	- 1 727	14.1%	-7 845	-6 235	25.8%
EBITA before restructuring	1 534	1 426	7.5%	3 933	3 428	14.7%
EBITA margin	22.4%	22.2%	0.2%	17.2%	17.8%	-0.5%
Restructuring	-193	-73		-336	-221	
Financial net	-146	-204		-664	-751	
Profit before tax	1 070	1 056	1.3%	2 634	2 126	23.9%


Q4 2009 Medical Systems Results

- Good revenue growth
- Favourable product mix

	2009	2008	Change	2009	2008	Change
<i>SEK million</i>	Q4	Q4	%	YTD	YTD	%
Net sales, SEK million	3 549	2 930	21.1%	11 255	8 416	33.7%
Gross margin %	55.3%	54.5%	0.8%	56.4%	56.1%	0.3%
Operating cost, SEK million	- 1 174	-883	33.0%	-4 510	-3 140	43.6%
EBITA before restructuring	880	773	13.8%	2 231	1 784	25.1%
EBITA margin	24.8%	26.4%	-1.6%	19.8%	21.2%	-1.4%
Restructuring	-83	-13		-197	-72	

Q4 2009 Medical Systems Highlights

- Integration of Boston Scientific Cardiac and Vascular Surgery divisions completed
- Datascope integration near completion
- Disposal of Percutaneous Heart Pump (PHP) project
- New sales offices in Mexico and Thailand
- New generation of modular OR theatre launched
- Next generation EVH device




Q4 2009 Extended Care Results

- Improved performance in logistics and transportation lifts gross margins
- Restructuring costs of SEK 24 million

<i>SEK million</i>	2009 Q4	2008 Q4	Change %	2009 YTD	2008 YTD	Change %
Net sales , SEK million	1 672	1 830	-8.6%	6 467	6 174	4.7%
Gross margin %	46.8%	44.1%	2.7%	45.8%	46.1%	-0.3%
Operating cost, SEK million	-484	-534	-9.4%	-2 074	-1 969	5.3%
EBITA before restructuring	325	302	7.6%	1 002	992	1.0%
EBITA margin	19.4%	16.5%	2.9%	15.5%	16.1%	-0.6%
Restructuring	-24	-60		-55	-145	

Q4 2009 Extended Care Highlights

- Merger of sales companies in France leading to annual profit improvement of SEK 15 million from 2011
- Launch of Alpha Response Mattress




Q4 2009 Infection Control Results

- Restructuring costs of SEK 85 million
- Continued pricing and cost discipline

	2009	2008	Change	2009	2008	Change
<i>SEK million</i>	Q4	Q4	%	YTD	YTD	%
Net sales , SEK million	1 624	1 664	-2.4%	5 094	4 682	8.8%
Gross margin %	39.3%	39.5%	-0.2%	38.2%	37.7%	0.5%
Operating cost, SEK million	-313	-310	1.0%	-1 261	-1 126	12.0%
EBITA before restructuring	329	351	-6.3%	700	652	7.4%
EBITA margin	20.3%	21.1%	-0.8%	13.7%	13.9%	-0.2%
Restructuring	-85	0		-85	-3	

Q4 2009 Infection Control Highlights

- Relocation of production from Germany and Denmark leading to annual savings of approx SEK 40 million from 2011
- New sales company in Hongkong



Consolidated cash flow statement

	2009	2008	2009	2008
<i>SEK million</i>	Q4	Q4	YTD	YTD
EBITDA	1 550	1 540	4 446	3 846
Restructuring Cost expenses	193	74	336	221
Restructuring costs paid	-85	-104	-202	-223
Adjustments for items not included in cash flow	24	-12	41	43
Financial items	-146	-204	-436	-751
Taxes paid	-311	-148	-653	-618
Cash flow before changes in working capital	1 225	1 146	3 532	2 518
Changes in working capital				
Stock-in-trade	592	77	-6	-575
Current receivables	-467	-747	745	-360
Current operating liabilities	318	-20	-271	191
Cash flow from operations	1 668	456	4 000	1 774

Financials

	2009	2008	2009	2008
<i>SEK million</i>	Q4	Q4	YTD	YTD
Cash conversion, %			90.0%	46.1%
Net Debt			16 296	13 648
Equity			12 562	10 676
Equity/assets ratio, per cent			33.5%	32.3%
Net debt/equity ratio multiple			129.7%	126.2%

Outlook

- Good improvement in organic orders and revenue growth
 - Improving demand situation in USA and emerging markets
 - Stable demand situation in Europe
- Continued good growth in pre-tax profit
- Restructuring costs will drop significantly in 2010
- Favorable currency hedges

GETINGE GROUP



QUESTIONS & ANSWERS

Forward looking information

This document contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.